Interactions between malaria and human immunodeficiency virus anno 2014

Clinical Microbiology and Infection

Volumn 20, Issue 4, 2014, Pages 278-285

  Van geertruyden, J P ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Clinical epidemiology; Diagnosis; HIV; Immunology; Interactions; Malaria; Public health; Review; Treatment

Indexed keywords

AMODIAQUINE PLUS ARTESUNATE; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; COTRIMOXAZOLE; DIHYDROARTEMISININ PLUS PIPERAQUINE; EFAVIRENZ; FOLIC ACID ANTAGONIST; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE;

ANTIMALARIAL ACTIVITY; ANTIVIRAL THERAPY; BED NET; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CYTOKINE RESPONSE; DISEASE COURSE; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG SAFETY; EPIDEMIOLOGY; HEALTH CARE ACCESS; HETEROSEXUALITY; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IN VIVO STUDY; INFECTION PREVENTION; MALARIA; MIXED INFECTION; MORBIDITY; PATHOPHYSIOLOGY; PATIENT CARE; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; T LYMPHOCYTE ACTIVATION; TH1 CELL; TREATMENT OUTCOME; UPREGULATION; VIRUS LOAD;

CLINICAL EPIDEMIOLOGY; DIAGNOSIS; HIV; IMMUNOLOGY; INTERACTIONS; MALARIA; PUBLIC HEALTH; REVIEW; TREATMENT;

ANTI-HIV AGENTS; ANTIMALARIALS; HIV INFECTIONS; HUMANS; MALARIA; TREATMENT OUTCOME;

EID: 84895948012     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12597     Document Type: Review

References (76)

1. Kedzierska K, Crowe SM. Cytokines and HIV-1: interactions and clinical implications. Antivir Chem Chemother 2001; 12: 133-150.
2. Manyando C, Njunju EM, D'Alessandro U, Van Geertruyden JP. Safety and efficacy of co-trimoxazole for treatment and prevention of Plasmodium falciparum malaria: a systematic review. PLoS ONE 2013; 8: e56916.
3. Mermin J, Ekwaru JP, Liechty CA et al. Effect of co-trimoxazole prophylaxis, antiretroviral therapy, and insecticide-treated bednets on the frequency of malaria in HIV-1-infected adults in Uganda: a prospective cohort study. Lancet 2006; 367: 1256-1261.
4. Artavanis-Tsakonas K, Tongren JE, Riley EM. The war between the malaria parasite and the immune system: immunity, immunoregulation and immunopathology. Clin Exp Immunol 2003; 133: 145-152.
5. Clerici M, Shearer GM. The Th1-Th2 hypothesis of HIV infection: new insights. Immunol Today 1994; 15: 575-581.
6. Nnedu ON, O'Leary MP, Mutua D et al. Humoral immune responses to Plasmodium falciparum among HIV-1-infected Kenyan adults. Proteomics Clin Appl 2011; 5: 613-623.
7. Chavale H, Santos-Oliveira JR, Da-Cruz AM, Enosse S. Enhanced T cell activation in Plasmodium falciparum malaria-infected human immunodeficiency virus-1 patients from Mozambique. Mem Inst Oswaldo Cruz 2012; 107: 985-992.
8. Ludlow LE, Zhou J, Tippett E et al. HIV-1 inhibits phagocytosis and inflammatory cytokine responses of human monocyte-derived macrophages to P. falciparum infected erythrocytes. PLoS ONE 2012; 7: e32102.
9. Van Geertruyden JP, Van EE, Yosaatmadja F et al. The relationship of Plasmodium falciparum humoral immunity with HIV-1 immunosuppression and treatment efficacy in Zambia. Malar J 2009; 8: 258-266.
10. ter Kuile FO, Parise ME, Verhoeff FH et al. The burden of co-infection with human immunodeficiency virus type 1 and malaria in pregnant women in sub-saharan Africa. Am J Trop Med Hyg 2004; 71: 41-54.
11. Lawn SD. AIDS in Africa: the impact of coinfections on the pathogenesis of HIV-1 infection. J Infect 2004; 48: 1-12.
12. Worku S, Bjorkman A, Troye-Blomberg M, Jemaneh L, Farnert A, Christensson B. Lymphocyte activation and subset redistribution in the peripheral blood in acute malaria illness: distinct gammadelta+ T cell patterns in Plasmodium falciparum and P. vivax infections. Clin Exp Immunol 1997; 108: 34-41.
13. Orlov M, Vaida F, Finney OC et al. P. falciparum enhances HIV replication in an experimental malaria challenge system. PLoS ONE 2012; 7: e39000.
14. Hoffman IF, Jere CS, Taylor TE et al. The effect of Plasmodium falciparum malaria on HIV-1 RNA blood plasma concentration. AIDS 1999; 13: 487-494.
15. Greenwood BM, Oduloju AJ, Stratton D. Lymphocyte changes in acute malaria. Trans R Soc Trop Med Hyg 1977; 71: 408-410.
16. Hviid L, Kurtzhals JA, Goka BQ, Oliver-Commey JO, Nkrumah FK, Theander TG. Rapid reemergence of T cells into peripheral circulation following treatment of severe and uncomplicated Plasmodium falciparum malaria. Infect Immun 1997; 65: 4090-4093.
17. Van Geertruyden JP, Mulenga M, Kasongo W et al. CD4 T-cell count and HIV-1 infection in adults with uncomplicated malaria. J Acquir Immune Defic Syndr 2006; 43: 363-367.
18. Tkachuk AN, Moormann AM, Poore JA et al. Malaria enhances expression of CC chemokine receptor 5 on placental macrophages. J Infect Dis 2001; 183: 967-972.
19. Inion I, Mwanyumba F, Gaillard P et al. Placental malaria and perinatal transmission of human immunodeficiency virus type 1. J Infect Dis 2003; 188: 1675-1678.
20. Mwapasa V, Rogerson SJ, Molyneux ME et al. The effect of Plasmodium falciparum malaria on peripheral and placental HIV-1 RNA concentrations in pregnant Malawian women. AIDS 2004; 18: 1051-1059.
21. Ayisi JG, van Eijk AM, Newman RD et al. Maternal malaria and perinatal HIV transmission, western Kenya. Emerg Infect Dis 2004; 10: 643-652.
22. Brahmbhatt H, Kigozi G, Wabwire-Mangen F et al. The effects of placental malaria on mother-to-child HIV transmission in Rakai, Uganda. AIDS 2003; 17: 2539-2541.
23. Ned RM, Moore JM, Chaisavaneeyakorn S, Udhayakumar V. Modulation of immune responses during HIV-malaria co-infection in pregnancy. Trends Parasitol 2005; 21: 284-291.
24. Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect 1999; 75: 3-17.
25. Wasserheit JN. Epidemiological synergy. Interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases. Sex Transm Dis 1992; 19: 61-77.
26. Abu-Raddad LJ, Patnaik P, Kublin JG. Dual infection with HIV and malaria fuels the spread of both diseases in sub-Saharan Africa. Science 2006; 314: 1603-1606.
27. Kublin JG, Patnaik P, Jere CS et al. Effect of Plasmodium falciparum malaria on concentration of HIV-1-RNA in the blood of adults in rural Malawi: a prospective cohort study. Lancet 2005; 365: 233-240.
28. Mermin J, Lule J, Ekwaru JP et al. Cotrimoxazole prophylaxis by HIV-infected persons in Uganda reduces morbidity and mortality among HIV-uninfected family members. AIDS 2005; 19: 1035-1042.
29. Korenromp EL, Williams BG, de Vlas SJ et al. Malaria attributable to the HIV-1 epidemic, sub-Saharan Africa. Emerg Infect Dis 2005; 11: 1410-1419.
30. Cuadros DF, Branscum AJ, Garcia-Ramos G. No evidence of association between HIV-1 and malaria in populations with low HIV-1 prevalence. PLoS ONE 2011; 6: e23458.
31. Van Geertruyden JP, Menten J, Colebunders R, Korenromp E, D'Alessandro U. The impact of HIV-1 on the malaria parasite biomass in adults in sub-Saharan Africa contributes to the emergence of antimalarial drug resistance. Malar J 2008; 7: 134-146.
32. Royce RA, Sena A, Cates W Jr, Cohen MS. Sexual transmission of HIV. N Engl J Med 1997; 336: 1072-1078.
33. Brentlinger PE, Behrens CB, Micek MA. Challenges in the concurrent management of malaria and HIV in pregnancy in sub-Saharan Africa. Lancet Infect Dis 2006; 6: 100-111.
34. Whitworth J, Morgan D, Quigley M et al. Effect of HIV-1 and increasing immunosuppression on malaria parasitaemia and clinical episodes in adults in rural Uganda: a cohort study. Lancet 2000; 356: 1051-1056.
35. French N, Nakiyingi J, Lugada E, Watera C, Whitworth JA, Gilks CF. Increasing rates of malarial fever with deteriorating immune status in HIV-1-infected Ugandan adults. AIDS 2001; 15: 899-906.
36. Patnaik P, Jere CS, Miller WC et al. Effects of HIV-1 serostatus, HIV-1 RNA concentration, and CD4 cell count on the incidence of malaria infection in a cohort of adults in rural Malawi. J Infect Dis 2005; 192: 984-991.
37. Laufer MK, van Oosterhout JJ, Thesing PC et al. Impact of HIV-associated immunosuppression on malaria infection and disease in Malawi. J Infect Dis 2006; 193: 872-878.
38. Grimwade K, French N, Mbatha DD, Zungu DD, Dedicoat M, Gilks CF. Childhood malaria in a region of unstable transmission and high human immunodeficiency virus prevalence. Pediatr Infect Dis J 2003; 22: 1057-1063.
39. Cohen C, Karstaedt A, Frean J et al. Increased prevalence of severe malaria in HIV-infected adults in South Africa. Clin Infect Dis 2005; 41: 1631-1637.
40. Grimwade K, French N, Mbatha DD, Zungu DD, Dedicoat M, Gilks CF. HIV infection as a cofactor for severe falciparum malaria in adults living in a region of unstable malaria transmission in South Africa. AIDS 2004; 18: 547-554.
41. Chalwe V, Van Geertruyden JP, Mukwamataba D et al. Increased risk for severe malaria in HIV-1-infected adults, Zambia. Emerg Infect Dis 2009; 15: 749-756.
42. Sloand E. Hematologic complications of HIV infection. AIDS Rev 2005; 7: 187-196.
43. Sullivan PS, Hanson DL, Chu SY, Jones JL, Ward JW. Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: results from the multistate adult and adolescent spectrum of HIV disease surveillance project. Blood 1998; 91: 301-308.
44. Markle HV. Cobalamin. Crit Rev Clin Lab Sci 1996; 33: 247-356.
45. Spivak JL, Barnes DC, Fuchs E, Quinn TC. Serum immunoreactive erythropoietin in HIV-infected patients. JAMA 1989; 261: 3104-3107.
46. van Eijk AM, Ayisi JG, ter Kuile FO et al. Malaria and human immunodeficiency virus infection as risk factors for anemia in infants in Kisumu, western Kenya. Am J Trop Med Hyg 2002; 67: 44-53.
47. Otieno RO, Ouma C, Ong'echa JM et al. Increased severe anemia in HIV-1-exposed and HIV-1-positive infants and children during acute malaria. AIDS 2006; 20: 275-280.
48. Van Geertruyden JP, Mulenga M, Chalwe V et al. Impact of HIV-1 infection on the hematological recovery after clinical malaria. J Acquir Immune Defic Syndr 2009; 50: 200-205.
49. Ayisi JG, van Eijk AM, ter Kuile FO et al. The effect of dual infection with HIV and malaria on pregnancy outcome in western Kenya. AIDS 2003; 17: 585-594.
50. Ticconi C, Mapfumo M, Dorrucci M et al. Effect of maternal HIV and malaria infection on pregnancy and perinatal outcome in Zimbabwe. J Acquir Immune Defic Syndr 2003; 34: 289-294.
51. Bloland PB, Wirima JJ, Steketee RW, Chilima B, Hightower A, Breman JG. Maternal HIV infection and infant mortality in Malawi: evidence for increased mortality due to placental malaria infection. AIDS 1995; 9: 721-726.
52. van Eijk AM, Ayisi JG, ter Kuile FO et al. Risk factors for malaria in pregnancy in an urban and peri-urban population in western Kenya. Trans R Soc Trop Med Hyg 2002; 96: 586-592.
53. Whitworth JA, Hewitt KA. Effect of malaria on HIV-1 progression and transmission. Lancet 2005; 365: 196-197.
54. Mermin J, Lule JR, Ekwaru JP. Association between malaria and CD4 cell count decline among persons with HIV. J Acquir Immune Defic Syndr 2006; 41: 129-130.
55. Bentwich Z. Concurrent infections that rise the HIV viral load. J HIV Ther 2003; 8: 72-75.
56. Kamya MR, Gasasira AF, Achan J et al. Effects of trimethoprim-sulfamethoxazole and insecticide-treated bednets on malaria among HIV-infected Ugandan children. AIDS 2007; 21: 2059-2066.
57. Mermin J, Lule J, Ekwaru JP et al. Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet 2004; 364: 1428-1434.
58. Thera MA, Sehdev PS, Coulibaly D et al. Impact of trimethoprim-sulfamethoxazole prophylaxis on falciparum malaria infection and disease. J Infect Dis 2005; 192: 1823-1829.
59. Sandison TG, Homsy J, Arinaitwe E et al. Protective efficacy of co-trimoxazole prophylaxis against malaria in HIV exposed children in rural Uganda: a randomised clinical trial. BMJ 2011; 342: d1617.
60. Skinner-Adams TS, McCarthy JS, Gardiner DL, Andrews KT. HIV and malaria co-infection: interactions and consequences of chemotherapy. Trends Parasitol 2008; 24: 264-271.
61. Kredo T, Mauff K, Van der Walt JS et al. Interaction between artemether-lumefantrine and nevirapine-based antiretroviral therapy in HIV-1-infected patients. Antimicrob Agents Chemother 2011; 55: 5616-5623.
62. Byakika-Kibwika P, Lamorde M, Mayito J et al. Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. J Antimicrob Chemother 2012; 67: 2213-2221.
63. Achan J, Kakuru A, Ikilezi G et al. Antiretroviral agents and prevention of malaria in HIV-infected Ugandan children. N Engl J Med 2012; 367: 2110-2118.
64. Violari A, Lindsey JC, Hughes MD et al. Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children. N Engl J Med 2012; 366: 2380-2389.
65. Gasasira AF, Kamya MR, Achan J et al. High risk of neutropenia in HIV-infected children following treatment with artesunate plus amodiaquine for uncomplicated malaria in Uganda. Clin Infect Dis 2008; 46: 985-991.
66. German P, Greenhouse B, Coates C et al. Hepatotoxicity due to a drug interaction between amodiaquine plus artesunate and efavirenz. Clin Infect Dis 2007; 44: 889-891.
67. Soyinka JO, Onyeji CO, Omoruyi SI, Owolabi AR, Sarma PV, Cook JM. Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administration. Br J Clin Pharmacol 2010; 69: 262-270.
68. ter Kuile FO, van Eijk AM, Filler SJ. Effect of sulfadoxine-pyrimethamine resistance on the efficacy of intermittent preventive therapy for malaria control during pregnancy: a systematic review. JAMA 2007; 297: 2603-2616.
69. Mathanga DP, Uthman OA, Chinkhumba J. Intermittent preventive treatment regimens for malaria in HIV-positive pregnant women. Cochrane Database Syst Rev 2011: CD006689.
70. Muller O, Moser R. The clinical and parasitological presentation of Plasmodium falciparum malaria in Uganda is unaffected by HIV-1 infection. Trans R Soc Trop Med Hyg 1990; 84: 336-338.
71. Colebunders R, Bahwe Y, Nekwei W et al. Incidence of malaria and efficacy of oral quinine in patients recently infected with human immunodeficiency virus in Kinshasa. Zaire J Infect 1990; 21: 167-173.
72. Greenberg AE, Nsa W, Ryder RW et al. Plasmodium falciparum malaria and perinatally acquired human immunodeficiency virus type 1 infection in Kinshasa, Zaire. A prospective, longitudinal cohort study of 587 children. N Engl J Med 1991; 325: 105-109.
73. Kamya MR, Kigonya CN, McFarland W. HIV infection may adversely affect clinical response to chloroquine therapy for uncomplicated malaria in children. AIDS 2001; 15: 1187-1188.
74. Birku Y, Mekonnen E, Bjorkman A, Wolday D. Delayed clearance of Plasmodium falciparum in patients with human immunodeficiency virus co-infection treated with artemisinin. Ethiop Med J 2002; 40(suppl 1): 17-26.
75. Kamya MR, Gasasira AF, Yeka A et al. Effect of HIV-1 infection on antimalarial treatment outcomes in Uganda: a population-based study. J Infect Dis 2006; 193: 9-15.
76. Van Geertruyden JP, Mulenga M, Mwananyanda L et al. HIV-1 immune suppression and antimalarial treatment outcome in Zambian adults with uncomplicated malaria. J Infect Dis 2006; 194: 917-925.